Expression of heregulin by mouse mammary tumor cells: Role in activation of ErbB receptors
✍ Scribed by M. Schmitt; M.P. Walker; R.G. Richards; W.P. Bocchinfuso; T. Fukuda; D. Medina; F.S. Kittrell; K.S. Korach; R.P. DiAugustine
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 401 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20180
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The inappropriate activation of one or more members of the ErbB family of receptor tyrosine kinases [ErbB‐1 (EGFR), ErbB‐2, ErbB‐3, ErbB‐4] has been linked with oncogenesis. ErbB‐2 is frequently coexpressed with ErbB‐3 in breast cancer cells and in the presence of the ligand heregulin (HRG) the ErbB‐2/ErbB‐3 receptors form a signaling heterodimer that can affect cell proliferation and apoptosis. The major goal of the present study was to determine whether endogenous HRG causes autocrine/paracrine activation of ErbB‐2/ErbB‐3 and contributes to the proliferation of mammary epithelial tumor cells. Tyrosine‐phosphorylated (activated) ErbB‐2 and ErbB‐3 receptors were detected in the majority of extracts from tumors that had formed spontaneously or as a result of oncogene expression. HRG‐1 transcripts and protein were found in the epithelial cells of most of these mouse mammary tumors. Various mouse mammary cell lines also contained activated ErbB‐2/ErbB‐3 and HRG transcripts. A ∼50 kDa C‐terminal fragment of pro‐HRG was detected, which indicates that the HRG‐1 precursor is readily processed by these cells. It is likely that the secreted mature HRG activated the ErbB‐2/3 receptors. Addition of an antiserum against HRG to the mammary epithelial tumor cell line TM‐6 reduced ErbB‐3 Tyr‐phosphorylation. Treatment with HRG‐1 siRNA oligonucleotides or infection with a retroviral construct to stably express HRG siRNA effectively reduced HRG protein levels, ErbB‐2/ErbB‐3 activation, and the rate of proliferation, which could be reversed by the addition of HRG. The cumulative findings from these experiments show that coexpression of the HRG ligand contributes to activation of ErbB‐2/Erb‐3 in mouse mammary tumor cells in an autocrine or paracrine fashion. Published 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract ErbB3 receptor tyrosine kinase has been shown to induce tumor progression in several types of cancer through heterodimerization with ErbB2. However, the role of ErbB3 and its ligand heregulin (HRG) in tumor metastasis remains poorly understood. In the present study, we tried to clarify
The mouse mammary tumor virus enters mammary epithelial cells via a plasma membrane protein that binds to a viral envelope glycoprotein, gp52. In intact cells, this gp52 receptor can be phosphorylated by activators of protein kinase A and protein kinase C (PKC), but this modification does not occur
The erbB-2/neu oncogene is frequently over-expressed in many different tumors in humans, including those of breast and ovary. The oncogene encodes a receptor tyrosine kinase closely related to the epidermal-growth-factor receptor. We studied effects on differentiation and cell death of erbB-2/neu du
## Abstract The ErbB family of receptor kinases is composed of four members: epidermal growth factor receptor (EGFR/ErbB1), ErbB2/neu, ErbB3, and ErbB4. Amplification of the ErbB2/neu is found in about 30% of breast cancer patients and is associated with a poor prognosis. Heregulin (HRG) activates
Heregulin P1 was found to stimulate the anchorage-dependent, serum-free growth of nontransformed human MCF-1 OA mammary epithelial cells. Unlike epidermal growth factor, transforming growth factor a, or amphiregulin, heregulin P I was also able to induce the anchorage-independent growth of MCF-1OA c